The present invention provides monoclonal antibodies (MAbs) selective for theN-termini and C-termini of the gastrin hormone forms, gastrin-17 (G17),glycine-extended gastrin-17 (G17-Gly), gastrin-34 (G34) and glycine-extendedgastrin-34 (G34-Gly)； and the hybridomas that produce these MAbs. Alsoprovided are panels of MAbs useful for the detection and quantitation ofgastrin-17 (G17), glycine-extended gastrin-17 (G17-Gly), gastrin-34 (G34) andglycine-extended gastrin-34 (G34-Gly). These assays are useful for monitoringa gastrin-mediated disease or condition, or for monitoring the progress of acourse of therapy. The invention further provides solid phase assays includingimmunohistochemical (IHC) and immunofluorescence (IF) assays suitable fordetection and visualization of gastrin species in solid samples, such asbiopsy samples or tissue slices. Pharmaceutical compositions of the MAbs ofthe invention are also provided, along with methods of diagnosis, preventionand treatment of gastrin-mediated diseases or conditions. Methods ofevaluating a gastrin hormone-blocking treatment are described. The course of agastrin-mediated disease or condition may be monitored in a patient by meansof assay methods provided.
